share_log

康方生物：截至2023年12月31日止年度業績公告

AKESO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 18 10:52
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」或「公司」）公佈截至2023年12月31日止年度的綜合業績。公司總收入達人民幣4,526.3百萬元，同比增長440%，毛利為人民幣4,393.0百萬元，同比增長491%。年內盈利為人民幣1,942.4百萬元，去年同期為虧損人民幣1,422.2百萬元。公司主要收入來自於產品銷售及技術授權和技術合作，其中開坦尼®（卡度尼利，PD-1/CTLA-4）產品銷售額為人民幣1,357.8百萬元，同比增加149%。此外，公司與Summit Therapeutics Inc（納斯達克股票代碼：SMMT）的技術授權合作亦為公司貢獻顯著收入。康方生物持續推進其在研創新項目，涵蓋腫瘤、自身免疫及代謝性疾病領域，並在全球範圍內推動新藥產品的臨床開發、生產和商業化進程。
康方生物科技（開曼）有限公司（「康方生物」或「公司」）公佈截至2023年12月31日止年度的綜合業績。公司總收入達人民幣4,526.3百萬元，同比增長440%，毛利為人民幣4,393.0百萬元，同比增長491%。年內盈利為人民幣1,942.4百萬元，去年同期為虧損人民幣1,422.2百萬元。公司主要收入來自於產品銷售及技術授權和技術合作，其中開坦尼®（卡度尼利，PD-1/CTLA-4）產品銷售額為人民幣1,357.8百萬元，同比增加149%。此外，公司與Summit Therapeutics Inc（納斯達克股票代碼：SMMT）的技術授權合作亦為公司貢獻顯著收入。康方生物持續推進其在研創新項目，涵蓋腫瘤、自身免疫及代謝性疾病領域，並在全球範圍內推動新藥產品的臨床開發、生產和商業化進程。
Kangfang Biotechnology (Cayman) Limited (“Kangfang Biotech” or the “Company”) announces its comprehensive results for the year ended 31 December 2023. The company's total revenue reached RMB4,526.3 million, up 440% year-on-year, and gross profit was RMB4,393.0 million, an increase of 491% year-on-year. The profit for the year was RMB 1,942.4 million and the loss was RMB1,422.2 million in the same period last year. The Company's primary revenue comes from product sales and technical licensing and technical collaborations, with Caitani® (Cadonili, PD-1/CTLA-4) product sales of RMB1,357.8 million, an increase of 149% year-over-year. In addition, the company's technology licensing partnership with Summit Therapeutics Inc (Nasdaq Stock Code: SMMT) also contributed significantly to the company's revenue. Kangfang Bios continues to advance its innovative research projects covering the fields of oncology, autoimmune and metabolic diseases, and drives the clinical development, production and commercialization of new drug products globally.
Kangfang Biotechnology (Cayman) Limited (“Kangfang Biotech” or the “Company”) announces its comprehensive results for the year ended 31 December 2023. The company's total revenue reached RMB4,526.3 million, up 440% year-on-year, and gross profit was RMB4,393.0 million, an increase of 491% year-on-year. The profit for the year was RMB 1,942.4 million and the loss was RMB1,422.2 million in the same period last year. The Company's primary revenue comes from product sales and technical licensing and technical collaborations, with Caitani® (Cadonili, PD-1/CTLA-4) product sales of RMB1,357.8 million, an increase of 149% year-over-year. In addition, the company's technology licensing partnership with Summit Therapeutics Inc (Nasdaq Stock Code: SMMT) also contributed significantly to the company's revenue. Kangfang Bios continues to advance its innovative research projects covering the fields of oncology, autoimmune and metabolic diseases, and drives the clinical development, production and commercialization of new drug products globally.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more